Building functional biological substitutes through the integration of scaffolds, cells, and signaling molecules to restore, maintain, or improve tissue function
Tissue engineering is an interdisciplinary field that applies principles from biology, materials science, and engineering to develop biological substitutes that can restore, maintain, or improve the function of damaged or diseased tissues. The field emerged in the 1980s and has since evolved from academic research to clinical reality.
The classic tissue engineering paradigm involves three key components working in concert:
This "triad" approach allows researchers and clinicians to create living tissue constructs that can integrate with the body's natural healing processes, offering solutions for conditions ranging from burn wounds to organ failure.
Tissue engineering offers the promise of eliminating transplant waiting lists by creating patient-specific tissues and organs, reducing healthcare costs, and improving quality of life for millions suffering from tissue damage and organ failure.[4]
Scaffolds serve as the structural foundation for tissue engineering, providing a three-dimensional template that guides cell attachment, proliferation, and differentiation. The ideal scaffold must balance mechanical properties, degradation rate, porosity, and biocompatibility to match the target tissue.
Derived from biological sources, these materials offer excellent biocompatibility and contain native binding sites for cell adhesion. They closely mimic the extracellular matrix environment.
Manufactured materials with precisely tunable mechanical properties, degradation rates, and porosity. Offer reproducibility and scalability for clinical manufacturing.
Water-swollen polymer networks that mimic soft tissue environments. Excellent for cell encapsulation and can be engineered for injectable delivery or 3D bioprinting.
Native tissue stripped of cells, preserving the original architecture and biochemical composition. Provides tissue-specific microenvironments that guide cell behavior.
The choice of cell source significantly impacts tissue engineering outcomes. Each source offers distinct advantages and limitations in terms of availability, expansion potential, immunogenicity, and differentiation capacity.
Cells harvested directly from patient tissue (autologous) or donors (allogeneic). Maintain native phenotype and function.
Multipotent cells from bone marrow, adipose tissue, or umbilical cord. Can differentiate into bone, cartilage, fat.
Adult cells reprogrammed to embryonic-like state. Can differentiate into any cell type in the body.
Derived from early embryos, true pluripotent cells representing the gold standard for differentiation potential.
Bioreactors provide controlled environments for tissue maturation, delivering nutrients, removing metabolic waste, and applying mechanical stimuli that mimic physiological conditions. Mechanical loading is essential for developing functional musculoskeletal and cardiovascular tissues.
Simple mixing culture for uniform nutrient distribution and construct suspension
Simulated microgravity environment for 3D tissue assembly with low shear
Continuous flow through scaffolds for improved mass transfer in thick constructs
Cyclic strain, compression, or tension to develop load-bearing tissues
Pulsed electrical fields for cardiac and neural tissue maturation
Physiological pressure waveforms for blood vessel conditioning
Tissues in the body constantly experience mechanical forces - hearts beat, muscles contract, bones bear weight. Without these forces during development, engineered tissues remain immature with inferior mechanical properties. Key findings include:
The greatest obstacle to engineering thick, metabolically active tissues is providing adequate blood supply. Cells cannot survive more than 100-200 micrometers from a capillary - the diffusion limit for oxygen and nutrients. Without vascularization, engineered tissues thicker than ~1mm suffer core necrosis.
Current strategies to address vascularization:
Tissue engineering has achieved varying levels of clinical success depending on tissue complexity. Simpler, avascular tissues have reached clinical application, while complex vascularized organs remain in development.
Epidermal and dermal substitutes for burns, chronic wounds, and reconstructive surgery
FDA ApprovedArticular cartilage repair for knee injuries and osteoarthritis treatment
FDA ApprovedBone grafts and scaffolds for fracture repair and spinal fusion
FDA ApprovedCorneal epithelial sheets for limbal stem cell deficiency
Approved (EU/Japan)Myocardial patches to repair heart tissue after infarction
Clinical TrialsTissue-engineered vascular grafts for bypass surgery
Clinical TrialsBladder augmentation for spina bifida patients
Clinical TrialsHepatocyte-based constructs for liver support and regeneration
Research PhaseTissue engineering has transitioned from laboratory research to clinical reality, with several products achieving regulatory approval and widespread clinical use. The field continues to expand into new therapeutic areas.
Tissue engineering increasingly integrates with regenerative medicine approaches, combining engineered constructs with endogenous repair mechanisms. This includes:
Apligraf, Dermagraft, PuraPly for wound healing; leader in skin substitutes
Dermal Regeneration Template, wound care matrices, orthopedic biologics
REGRANEX, SANTYL, wound care portfolio and orthopedic regenerative products
MACI (cartilage repair), Epicel (autologous skin), cell therapy leader
INFUSE bone graft, biologic spine products, regenerative technologies
DeNovo NT, cartilage repair, orthopedic biologics and regenerative portfolio
Plant-derived recombinant human collagen for tissue engineering applications
Human Acellular Vessel (HAV) - off-the-shelf bioengineered blood vessels
Apligraf was the first FDA-approved product containing living cells, approved in 1998 for venous leg ulcers and expanded to diabetic foot ulcers. This bilayered skin construct contains both keratinocytes and fibroblasts from neonatal foreskin, providing both structural support and growth factors that accelerate wound healing. It demonstrated that living tissue-engineered products could be manufactured at scale, shipped to hospitals, and integrated into routine clinical care.
Dr. Anthony Atala's team at Wake Forest achieved a landmark success by implanting tissue-engineered bladders in young patients with myelomeningocele (spina bifida). Using a biodegradable scaffold seeded with the patients' own bladder cells (urothelial and smooth muscle cells), the team created functional bladder augmentations. Long-term follow-up showed the constructs integrated successfully, with patients maintaining improved bladder capacity and kidney function over a decade later.
Humacyte developed the Human Acellular Vessel (HAV), a bioengineered blood vessel grown from human cells in a bioreactor, then decellularized to create an off-the-shelf product. Unlike autologous vein grafts (which require harvesting from patients) or synthetic grafts (which have high infection and thrombosis rates), HAV provides a readily available, living tissue that remodels and becomes populated by the patient's own cells after implantation. Phase III trials for hemodialysis access showed superior patency and lower infection rates.
Tissue-engineered products face complex regulatory requirements based on their composition, intended use, and risk level. Key regulatory frameworks include:
The FDA has approved over 15 tissue-engineered products, with many more in clinical development. The agency has issued guidance documents specific to wound healing products, cartilage repair, and cardiovascular tissues to clarify regulatory expectations.
Despite significant progress, tissue engineering faces several key challenges that must be overcome to realize its full potential:
Emerging technologies driving future progress:
Tissue engineering is an interdisciplinary field that combines principles from biology, materials science, and engineering to develop biological substitutes that restore, maintain, or improve tissue function. It typically involves three key components: scaffolds (structural support), cells (the building blocks), and signaling molecules (growth factors that guide development).
Scaffolds fall into three main categories: 1) Natural biomaterials like collagen, fibrin, alginate, and decellularized ECM that offer excellent biocompatibility, 2) Synthetic polymers like PLA, PGA, PLGA, and PCL that provide tunable mechanical properties and degradation rates, and 3) Hydrogels that mimic soft tissue environments and can encapsulate cells in 3D matrices.
Common cell sources include: primary cells (harvested directly from patients but limited in quantity), adult stem cells (like MSCs from bone marrow or adipose tissue), induced pluripotent stem cells (iPSCs that can differentiate into any cell type), and embryonic stem cells. Each source has trade-offs between availability, expansion potential, and differentiation capacity.
Bioreactors provide controlled environments for tissue development, delivering nutrients, removing waste, and applying mechanical stimulation that mimics physiological conditions. They can apply cyclic strain, shear stress, compression, or electrical stimulation to promote tissue maturation. Advanced bioreactors enable perfusion culture for larger constructs requiring vascular-like flow.
Cells cannot survive more than 100-200 micrometers from a blood supply due to oxygen and nutrient diffusion limits. Creating functional vascular networks that integrate with host circulation remains the critical challenge for engineering thick, metabolically active tissues. Current strategies include prevascularization, angiogenic factor delivery, and co-culture with endothelial cells.
Successfully engineered tissues include: skin (FDA-approved products like Apligraf and Integra), cartilage (autologous chondrocyte implantation is standard of care), bone (scaffolds with osteogenic cells), cardiac patches (in clinical trials), bladder (pioneered by Wake Forest), cornea, blood vessels, and trachea. Simpler, avascular tissues have achieved clinical success faster than complex organs.
Leading companies include Organogenesis (Apligraf, Dermagraft skin substitutes), Integra LifeSciences (dermal regeneration templates), Smith & Nephew (wound care and orthopedic biologics), Vericel (MACI cartilage repair), Organovo (3D bioprinted tissues), and numerous startups focusing on specific tissue types. The global tissue engineering market is projected to exceed $30 billion by 2030.
Tissue engineered products are regulated based on composition and intended use. The FDA classifies them under biologics (CBER) if they contain living cells, devices (CDRH) for acellular scaffolds, or combination products. The 21 CFR Part 1271 framework governs human cells and tissues. Products may follow 510(k), PMA, or BLA pathways depending on complexity and risk level.
Experience interactive tissue engineering in our virtual lab environment
Tissue Builder Scaffold Designer All Technologies All Simulations